South Korea · Delayed Price · Currency is KRW SyntekaBio Statistics
Total Valuation
SyntekaBio has a market cap or net worth of KRW 30.06 billion. The enterprise value is 28.98 billion.
| Market Cap | 30.06B |
| Enterprise Value | 28.98B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SyntekaBio has 24.26 million shares outstanding. The number of shares has increased by 31.53% in one year.
| Current Share Class | 24.26M |
| Shares Outstanding | 24.26M |
| Shares Change (YoY) | +31.53% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 16.64% |
| Owned by Institutions (%) | n/a |
| Float | 20.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.74 |
| PB Ratio | 1.16 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.25.
| Current Ratio | 0.97 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.59 |
| Interest Coverage | -4.39 |
Financial Efficiency
Return on equity (ROE) is -59.96% and return on invested capital (ROIC) is -19.87%.
| Return on Equity (ROE) | -59.96% |
| Return on Assets (ROA) | -16.67% |
| Return on Invested Capital (ROIC) | -19.87% |
| Return on Capital Employed (ROCE) | -37.08% |
| Weighted Average Cost of Capital (WACC) | 10.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.64% in the last 52 weeks. The beta is 0.37, so SyntekaBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -77.64% |
| 50-Day Moving Average | 1,440.94 |
| 200-Day Moving Average | 2,825.76 |
| Relative Strength Index (RSI) | 43.74 |
| Average Volume (20 Days) | 543,472 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SyntekaBio had revenue of KRW 3.09 billion and -12.01 billion in losses. Loss per share was -598.39.
| Revenue | 3.09B |
| Gross Profit | 3.08B |
| Operating Income | -10.53B |
| Pretax Income | -12.01B |
| Net Income | -12.01B |
| EBITDA | -8.59B |
| EBIT | -10.53B |
| Loss Per Share | -598.39 |
Balance Sheet
The company has 7.46 billion in cash and 6.38 billion in debt, with a net cash position of 1.08 billion or 44.47 per share.
| Cash & Cash Equivalents | 7.46B |
| Total Debt | 6.38B |
| Net Cash | 1.08B |
| Net Cash Per Share | 44.47 |
| Equity (Book Value) | 25.93B |
| Book Value Per Share | 1,071.49 |
| Working Capital | -264.77M |
Cash Flow
In the last 12 months, operating cash flow was -10.40 billion and capital expenditures -441.74 million, giving a free cash flow of -10.84 billion.
| Operating Cash Flow | -10.40B |
| Capital Expenditures | -441.74M |
| Depreciation & Amortization | 1.95B |
| Net Borrowing | -15.08B |
| Free Cash Flow | -10.84B |
| FCF Per Share | -446.88 |
Margins
| Gross Margin | 99.95% |
| Operating Margin | -341.33% |
| Pretax Margin | -389.09% |
| Profit Margin | n/a |
| EBITDA Margin | -278.25% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SyntekaBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.53% |
| Shareholder Yield | -31.53% |
| Earnings Yield | -39.95% |
| FCF Yield | -36.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SyntekaBio has an Altman Z-Score of -0.73 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.73 |
| Piotroski F-Score | 4 |